Crofab
FDA Approves Dotarem, a New MRI Agent »
"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Crofab
Crofab Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
CroFab [crotalidae polyvalent immune fab) (ovine)] is used as an anti-venom to bites from certain snakes (e.g., rattlesnakes, cottonmouths/water moccasins, copperheads). It is an antivenin product. Common side effects include hives, rash, and itching.
Administration of antivenin should be initiated as soon as possible after crotalid snakebite in patients who develop signs of progressive envenomation (e.g., worsening local injury, coagulation abnormality, or systemic signs of envenomation). The recommended initial dose of CroFab is 4 to 6 vials. CroFab may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, CroFab should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our CroFab [crotalidae polyvalent immune fab) (ovine)] Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Crofab FDA Prescribing Information: Side Effects
(Adverse Reactions)
SIDE EFFECTS
- The majority of adverse reactions to CroFab (crotalidae polyvalent immune fab ovine) reported in clinical studies were mild or moderate in severity.
- The most common adverse events reported in the clinical studies were urticaria and rash. Adverse events involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 14 of the 42 patients (Table 6).
- Of the 25 patients who experienced adverse reactions, 3 patients experienced severe or serious adverse reactions. The 1 patient who experienced a serious adverse event had a recurrent coagulopathy due to envenomation, which required re-hospitalization and additional antivenin administration. This patient eventually made a complete recovery. The other 2 had severe adverse reactions that consisted of 1 patient who developed severe hives following treatment and 1 patient who developed a severe rash and pruritus several days following treatment. Both patients recovered following treatment with antihistamines and prednisone.
- One patient discontinued CroFab (crotalidae polyvalent immune fab ovine) therapy due to an allergic reaction.
Table 6. Incidence of Clinical Adverse Events in Studies
of CroFab (crotalidae polyvalent immune fab ovine) by Body System
| Adverse Events | n=42* Number of Events |
| Body as a Whole | |
| Back pain | 2 |
| Chest pain | 1 |
| Cellulitis | 1 |
| Wound infection | 1 |
| Chills | 1 |
| Allergic reaction† | 1 |
| Serum sickness | 1 |
| Skin and Appendages | |
| Urticaria | 7 |
| Rash | 5 |
| Pruritus | 3 |
| Subcutaneous nodule | 1 |
| Cardiovascular System | |
| Hypotension | 1 |
| Respiratory System | |
| Asthma | 1 |
| Cough | 1 |
| Increased sputum | 1 |
| Digestive System | |
| Nausea | 3 |
| Anorexia | 1 |
| Hematologic/Lymphatic | |
| Coagulation disorder | 3 |
| Ecchymosis | 1 |
| Musculoskeletal | |
| Myalgia | 1 |
| Nervous System | |
| Circumoral paresthesia | 1 |
| General paresthesia | 1 |
| Nervousness | 1 |
| *Of the 42 patients receiving CroFab (crotalidae polyvalent immune fab ovine) in the clinical studies,
25 experienced an adverse event. A total of 40 adverse events was experienced
by these 25 patients. †Allergic reaction consisted of urticaria, dyspnea and wheezing in 1 patient. |
|
In the 42 patients treated with CroFab (crotalidae polyvalent immune fab ovine) for minimal or moderate crotalid envenomations, there were 7 events classified as early serum reactions and 5 events classified as late serum reactions, and none were serious (Table 7). In the clinical studies, serum reactions consisted mainly of urticaria and rash, and all patients recovered without sequelae.
Table 7. Incidence of Early and Late Serum Reactions (Reactions
Associated with CroFab (crotalidae polyvalent immune fab ovine) Infusion)
| n=42* Number of Events |
|
| Early Serum Reactions | |
| Urticaria | 5 |
| Cough | 1 |
| Allergic reaction** | 1 |
| Late Serum Reactions | |
| Rash | 2 |
| Pruritus | 1 |
| Urticaria | 1 |
| Serum sickness† | 1 |
| *6 of 42 patients experienced an adverse event associated
with an early serum reaction and 4 experienced an adverse event associated
with a late serum reaction. Two additional patients were considered to have
a late serum reaction by the investigator, although no associated adverse
event was reported. **Allergic reaction consisted of urticaria, dyspnea and wheezing in 1 patient. †Serum sickness consisted of severe rash and pruritus in 1 patient. |
|
Read the entire FDA prescribing information for Crofab (Crotalidae Polyvalent Immune Fab Ovine) »
Additional Crofab Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
